Phase 3 Alzheimer's Disease Trial, Recruiting NCT03860857 Sponsor: University of California, Irvine Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT03860857
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 60 or older
  • People who speak fluent English or Spanish
  • People with vision and hearing good enough to complete computer-based and cognitive tests
  • People who are in generally good health, with no conditions expected to interfere with the study
  • People who are willing and able to participate for the full length of the study, including brain scans (MRI and PET)
  • People whose memory and thinking are considered normal, based on standard assessments used by the trial team (confirm specific scores with trial site)
  • People who feel they have noticed some changes in their memory or thinking, even if testing shows normal results

Who may not be able to join:

  • People with serious neurological conditions such as Parkinson's disease, multiple sclerosis, brain cysts, brain tumours, or brain aneurysms
  • People with significant other major health conditions (note: type 2 diabetes, high cholesterol, and high blood pressure are NOT disqualifying for this trial)
  • People with serious psychiatric conditions such as schizophrenia, bipolar disorder, or ADHD (note: depression and anxiety are NOT disqualifying for this trial)
  • People who already have a diagnosis of dementia or mild cognitive impairment
  • People who have had issues with alcohol or substance misuse within the past two years
  • People for whom an MRI scan is not safe — for example, those with a pacemaker, metal implants, aneurysm clips, artificial heart valves, ear implants, or metal fragments in the eyes, skin, or body; also people who are pregnant or trying to become pregnant
  • People for whom a PET scan is not safe — for example, those with significant prior exposure to radiation, or who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael A Yassa, PhD, University of California, Irvine

Phone: 949-824-0904

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of California, Irvine
Registry
ClinicalTrials.gov
Start date
1 May 2018
Est. completion
22 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Clinical Dementia Rating - Sum of Box Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov